Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors

Study Overview
=================
Brief Summary
-----------------
As the clinical manifestations of pituitary neuroendocrine tumors vary greatly, 2.7-15% of them are resistant to conventional treatments such as surgery, drug therapy and radiotherapy, and often relapse or regrow in the early postoperative period, which is invasive and has a poor prognosis. Therefore, it is important to find imaging, histological or serum molecular markers for early prediction of the invasiveness and clinical prognosis of pituitary neuroendocrine tumors. The aim of this study is to observe the changes of biomarkers and imaging features in serum or tissues of pituitary neuroendocrine tumors during the course of disease and treatment, and to explore the biomarkers and imaging features that can predict the proliferation, progression and recurrence risk of pituitary neuroendocrine tumors after medical or surgical treatment.

Official Title
-----------------
Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors

Conditions
-----------------
Pituitary Adenoma, Neuroendocrine Tumors

Intervention / Treatment
-----------------
* Other: diagnosed and treated reasonably according to the clinical guidelines and clinical pathways


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with pituitary neuroendocrine tumors: pituitary adenoma was diagnosed by clinical imaging, with or without pituitary hormone secretion function was confirmed by pituitary hormone detection. Exclusion Criteria: Previous pathological specimen suggested pituitary carcinoma. always have received radiation and chemotherapy or immune and targeted therapy of the patients. with known genetic syndrome can cause excessive secretion of hormones (such as Carney syndrome, McCune - Albright syndrome, multiple endocrine neoplasia type 1, acute interstitial pneumonia) patients. there are ectopic neuroendocrine tumor patients. within one month before the screening for major surgery, or within 3 months before screening for patients with sphenoid pituitary surgery. crisis of gland function (the pituitary gland, thyroid crisis, adrenal crisis). peripheral glands or other solid tumors in patients with severe disease or blood system. serious organ damage such as heart, kidney, liver, etc. with severe mental or nervous system disease. serious high blood glucose or poorly controlled hypertension or emergency patients.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pituitary neuroendocrine tumors<br>Patients with pituitary neuroendocrine tumors: pituitary adenoma was diagnosed by clinical imaging, with or without pituitary hormone secretion function was confirmed by pituitary hormone detection. | Other: diagnosed and treated reasonably according to the clinical guidelines and clinical pathways<br>* The clinical data and biological specimens of the selected patients were collected, and the patients were diagnosed and treated reasonably according to the clinical guidelines and clinical pathways. The prognosis and outcome of the disease within 5 years after discharge were observed.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease progression or recurrence after surgery | Disease'recurrence'corresponded to tumour detection at MRI and/or hormone hypersecretion in previously cured patients, while disease'progression'indicated the increase in size of post-operative tumour remnant in nonfunctioning tumours and/or relapse of hormone hypersecretion in functioning ones | up to 5 years |